This company is no longer active
Aerie Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 2/6
Key information
-190.6%
Debt to equity ratio
US$312.59m
Debt
| Interest coverage ratio | n/a |
| Cash | US$172.46m |
| Equity | -US$163.98m |
| Total liabilities | US$539.57m |
| Total assets | US$375.59m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0P0 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: 0P0 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: 0P0 has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: 0P0's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 0P0 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 0P0 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 13.9% per year.